CLINICAL_TRIALS trial_result · 2017-08-25

Clinical Trial Update: BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer [Phase 2]

Phase 2 trial evaluating BIBF 1120 as second-line treatment for small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Ji-youn Han | Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Recurrent | Phase 2 | Status: COMPLETED